Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vladimir Coric

Showing results (21-30 of 84) with videos related to

Pageof 9
Sort By:
CNS Drugs|August 14, 2008
Riluzole in the treatment of mood and anxiety disordersChristopher Pittenger, Vladimir Coric, Mounira Banasr, et al.
The Journal of Clinical Psychiatry|February 8, 2007
Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomaniaVladimir Coric, Ben Kelmendi, Christopher Pittenger, et al.
Journal of Obsessive-Compulsive and Related Disorders|May 3, 2016
Probing Implicit Learning in Obsessive-Compulsive Disorder: Moderating Role of Medication on the Weather Prediction TaskBenjamin Kelmendi, Thomas Adams, Ewgeni Jakubovski, et al.
Psychiatry (Edgmont (Pa. : Township))|November 25, 2010
Juveniles and competency to stand trialFrank Fortunati, Charles A Morgan, Humberto Temporini, et al.
Psychiatry (Edgmont (Pa. : Township))|November 25, 2010
The last will and testament and the psychiatristSeth Feuerstein, Vladimir Coric, Charles A Morgan, et al.
Psychiatry (Edgmont (Pa. : Township))|November 25, 2010
Forensic files: where have we been and where are we going?Seth Feuerstein, Vladimir Coric, Charles A Morgan, et al.
Clinical Pharmacology in Drug Development|April 19, 2023
Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open-Label, Single-Dose, Parallel-Group StudyRajinder Bhardwaj, Andrea Ivans, Joseph Stringfellow, et al.
Journal of Medical Economics|April 12, 2021
Novel acute therapies in the treatment of migraine: impact of re-dosing on cost-utility outcomesKarissa M Johnston, Gilbert L'italien, Linda Harris, et al.
Headache|March 28, 2022
Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United StatesLinda Harris, Gilbert L'Italien, Anil Kumar, et al.
The Journal of Headache and Pain|January 18, 2022
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201)Karissa Johnston, Linda Harris, Lauren Powell, et al.
Pageof 9

Showing results (21-30 of 84) with videos related to

Sort By:
Pageof 9
CNS Drugs|August 14, 2008
Riluzole in the treatment of mood and anxiety disordersChristopher Pittenger, Vladimir Coric, Mounira Banasr, et al.
The Journal of Clinical Psychiatry|February 8, 2007
Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomaniaVladimir Coric, Ben Kelmendi, Christopher Pittenger, et al.
Journal of Obsessive-Compulsive and Related Disorders|May 3, 2016
Probing Implicit Learning in Obsessive-Compulsive Disorder: Moderating Role of Medication on the Weather Prediction TaskBenjamin Kelmendi, Thomas Adams, Ewgeni Jakubovski, et al.
Psychiatry (Edgmont (Pa. : Township))|November 25, 2010
Juveniles and competency to stand trialFrank Fortunati, Charles A Morgan, Humberto Temporini, et al.
Psychiatry (Edgmont (Pa. : Township))|November 25, 2010
The last will and testament and the psychiatristSeth Feuerstein, Vladimir Coric, Charles A Morgan, et al.
Psychiatry (Edgmont (Pa. : Township))|November 25, 2010
Forensic files: where have we been and where are we going?Seth Feuerstein, Vladimir Coric, Charles A Morgan, et al.
Clinical Pharmacology in Drug Development|April 19, 2023
Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open-Label, Single-Dose, Parallel-Group StudyRajinder Bhardwaj, Andrea Ivans, Joseph Stringfellow, et al.
Journal of Medical Economics|April 12, 2021
Novel acute therapies in the treatment of migraine: impact of re-dosing on cost-utility outcomesKarissa M Johnston, Gilbert L'italien, Linda Harris, et al.
Headache|March 28, 2022
Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United StatesLinda Harris, Gilbert L'Italien, Anil Kumar, et al.
The Journal of Headache and Pain|January 18, 2022
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201)Karissa Johnston, Linda Harris, Lauren Powell, et al.
Pageof 9